Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.65 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.65 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19025071 | 0.95 | TYR (0.59) | TYRTRIM24TRIM33EGFRMAPT | |
| SCHEMBL20339391 | 0.92 | TYR (0.63) | TYRTRIM24TRIM33EGFRMAPT | |
| SCHEMBL22146620 | 0.92 | TYR (0.63) | TYRTRIM24TRIM33EGFRMAPT | |
| SCHEMBL8421788 | 0.87 | ERN1 (0.65) | TYRTRIM24TRIM33EGFRERN1 | |
| SCHEMBL19025099 | 0.85 | TYR (0.62) | TYRTRIM24TRIM33MAPTPOLB | |
| SCHEMBL4556765 | 0.85 | TYR (0.62) | TYRTRIM24TRIM33MAPTPOLB | |
| SCHEMBL1960093 | 0.85 | TYR (0.67) | TYRTRIM24TRIM33EGFRMAPT | |
| SCHEMBL28350957 | 0.84 | ALDH1A1 (0.46) | TYRTRIM24TRIM33MAPTAPP | |
| SCHEMBL10584941 | 0.83 | TYR (0.59) | TYRTRIM24TRIM33MAPTPOLB | |
| SCHEMBL7323609 | 0.83 | TRIM24 (0.58) | TYRTRIM24TRIM33MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| CN-101282725-A | Therapeutic agent for diabetes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-10-08 | — | — | CN | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | TYR 3418/4885TRIM24 3853/4885TRIM33 4537/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | TYR 3078/4885TRIM24 3797/4885TRIM33 4189/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | TYR 3418/4885TRIM24 3853/4885TRIM33 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.